Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. Read full article here: https://equity.guru/2021/06/07/lexaria-bioscience-lxx-c-releases-progress-report-for-first-human-clinical-study/